Prophecy in today's headlines

Arsenal of Antibiotics Not Being Restocked Due To Stalemate

This is one of those stories that you’re probably not hearing a lot about, but that doesn’t diminish the looming threat if it isn’t addressed soon.

Drug companies are abandoning the antibacterial business, citing high development costs, low return on investment and, increasingly, a nearly decade-long stalemate with the Food and Drug Administration over how to bring new antibiotics to market. Soon, doctors could be defenseless against bacteria that can resist all existing antibiotics,  resulting in what Dr. Brad Spellberg, an expert on antibiotic resistance called a  “catastrophic” situation.

Read More

Leave a Reply

Your email address will not be published.